Publications

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, The International Society for the Study of Women's Sexual Health, The North American Menopause Society, The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, The Royal College of Obstetricians and Gynaecologists, The International Society of Endocrinology, The Endocrine Society of Australia, and The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Click here to read more.

Category: Publications

Mayo Clinic Proceedings - Hypoactive Sexual Desire Disorder (HSDD) ISSWSH Expert Consensus Panel Review

The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efficacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efficacy data. Menopausal women with HSDD may benefit from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efficacy and short-term safety. Currently, flibanserin is the only Food and Drug Administration–approved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD significantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments. Click here to read more.

Category: Publications

The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women

Sexual problems are common in women of all ages. Despite their frequency and impact, female sexual dysfunction (FSDs) are often unrecognized and untreated in clinical settings. This POC describes core and advanced competencies in FSD for clinicians who are not sexual medicine specialists and serve as caregivers of women and, therefore, is useful for clinicians with any level of competence in sexual medicine. The goal of the POC is to provide guidance to clinicians regarding screening, education, management, and referral for women with sexual problems.

Click here to view the full article.

Category: Publications

Descriptors of Vulvodynia: A Multisocietal Definition Consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society)

Descriptors of Vulvodynia: A Multisocietal Definition Consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society): https://europepmc.org/abstract/med/30768446

Category: Publications

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health: https://journals.lww.com/menopausejournal/Abstract/2018/06000/Management_of_genitourinary_syndrome_of_menopause.6.aspx

Category: Publications

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Womens Sexual Health and The North American Menopause Society

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Womens Sexual Health and The North American Menopause Society: http://www.menopause.org/docs/default-source/2014/gsm-paper.pdf
Category: Publications

Save the Date

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Registration open for on-demand viewing

ISSWSH Annual Meeting 2021
March 5-7, 2021   40 days left
Virtual
Visit the Meeting Website

ISSWSH Fall Course 2021
October 7-10, 2021   257 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

Latest Tweets

You don't want to miss these outstanding guest lectures from #ISSM #ESSM #NAMS #IUGA #SSTAR #TheNetwork on March 6… https://t.co/fS8iJt3Hub ISSWSH
ISSWSH members only pay $40 to access our official #SlideDeck - that's a deal too good to pass up! https://t.co/vOWCdtgVfT ISSWSH
Register now to hear Dr. Giovanni Castellini's State of the Art Lecture "Sex and Food" on March 6 during… https://t.co/zhaQOej4OZ ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram